Biovica International AB (STU:9II) Change In Working Capital : €0.40 Mil (TTM As of Jan. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Biovica International AB Change In Working Capital?

Biovica International AB's change in working capital for the quarter that ended in Jan. 2025 was €0.21 Mil.

Biovica International AB's change in working capital for the fiscal year that ended in Apr. 2024 was €0.24 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Biovica International AB Change In Working Capital Historical Data

The historical data trend for Biovica International AB's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Change In Working Capital Chart

Biovica International AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Change In Working Capital

Get a 7-Day Free Trial

0.17

-0.09

0.17

0.68

0.24

Biovica International AB Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Working Capital	Get a 7-Day Free Trial															0.16	1.13	-0.62	-0.33	0.21

Biovica International AB Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.40 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Biovica International AB Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biovica International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (STU:9II) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

BIOVIC B:Sweden

Address

Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37

Website

https://www.biovica.com

Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines